Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

How risky is a second allo? A retrospective analysis of treatment-related mortality in patients receiving allogeneic stem cell transplantation for the second time

Retrospective Studies

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Potential factors influencing CAR-T cell manufacturing in terms of production failures and out of specification (OOS) products on behalf of EBMT - CTIWP

Closed Survey/Study

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator

Defining protective immune cell subsets and subpopulations thresholds following allogeneic hematopoietic stem cell transplantation

Retrospective Studies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator

Marina Cavazzana

Setting the stage for newborn screening and gene therapy: a disease-specific retrospective survey of FHL2 and 3

Retrospective Studies

Inherited disorders

Inborn Errors Working Party (IEWP)

Type of treatment

Principal investigator

Stephan Ehl, Despina Moshous, Claire Booth, Sujal Ghosh

Evaluation of Outcomes following Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with High-Risk Acute Myeloid Leukemia:

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Paediatric Diseases Working Party (PDWP)

Type of treatment

Allogeneic - Related

Allogeneic - Unrelated

Allogeneic - Haploidentical

Principal investigator

Akshay Sharma (Memphis, US)

Long-term survival after autologous or allogeneic transplantation for T-cell lymphoma: a retrospective analysis of the EBMT-Lymphoma Working Party

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Outcomes of Autologous and Allogeneic Stem Cell Transplantation in Patients with Hepatosplenic T-cell Lymphoma (HSTCL)

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Imke E. Karsten

Allogeneic Hematopoietic Cell Transplantation and CAR-T therapy for T-cell/histiocyte-rich Large B-cell Lymphoma (THRLBCL) A Retrospective Study of the EBMT Lymphoma Working Party

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Simon Renders, MD

Trends in Hematopoietic Stem Cell Transplantation for Patients with Diffuse Large B-Cell Lymphoma. A Retrospective Analysis of the Lymphoma WP of the EBMT

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Norbert Schmitz, Anna Sureda

Efficacy and toxicity of CAR T cell therapy in patients with primary and secondary central nervous system lymphoma

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

GoCART Coalition

Lymphoma Working Party (LWP)

Type of treatment

Principal investigator

Anna Ossami Saidy

Post-transplantation cyclophosphamide-based after HLA-matched versus haploidentical donor transplants in patients with Hodgkin lymphoma: a comparative study of the LWP EBMT

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Lymphoma Working Party (LWP)

Type of treatment

Allogeneic - Haploidentical

Principal investigator

Dr. Juan Montoro

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type of treatment

Principal investigator